KRAS mutation in primary ovarian serous borderline tumors correlates with tumor recurrence
Oncogenic activation of the mitogen-activated protein kinase (MAPK) pathway due to KRAS or BRAF gain-of-function mutation is frequently found in ovarian serous borderline tumor (SBT) and their extraovarian implants. We investigated mutational status of KRAS and BRAF of the primary ovarian SBTs that...
Saved in:
Published in | Virchows Archiv : an international journal of pathology Vol. 483; no. 1; pp. 71 - 79 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
Berlin/Heidelberg
Springer Berlin Heidelberg
01.07.2023
Springer Nature B.V |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Oncogenic activation of the mitogen-activated protein kinase (MAPK) pathway due to
KRAS
or
BRAF
gain-of-function mutation is frequently found in ovarian serous borderline tumor (SBT) and their extraovarian implants. We investigated mutational status of
KRAS
and
BRAF
of the primary ovarian SBTs that had a high stage presentation in correlation with clinical outcome. Among 39 consecutive primary SBTs with either invasive implants (20 cases) or non-invasive implants (19 cases),
KRAS
and
BRAF
mutational analysis was informative in 34 cases. Sixteen cases (47%) harbored a
KRAS
mutation, while 5 cases (15%) had a
BRAF
V600E mutation. High-stage disease (IIIC) was seen in 31% (5/16) of patients with a
KRAS
mutation and 39% (7/18) of patients without a
KRAS
mutation (
p
= 0.64).
KRAS
mutations were present in 9/16 (56%) tumors with invasive implants/LGSC versus 7/18 (39%) tumors with non-invasive implants (
p
= 0.31).
BRAF
mutation was seen in 5 cases with non-invasive implants. Tumor recurrence was seen in 31% (5/16) of patients with a
KRAS
mutation, compared to 6% (1/18) of patients without a
KRAS
mutation (
p
= 0.04). A
KRAS
mutation predicted an adverse disease-free survival (31% survival at 160 months) compared to those with wild-type
KRAS
(94% at 160 months; log-rank test,
p
= 0.037; HR 4.47). In conclusion,
KRAS
mutation in primary ovarian SBTs is significantly associated with a worse disease-free survival, independent of the high tumor stage or histological subtypes of extraovarian implant. KRAS mutation testing of primary ovarian SBT may servce as a useful biomarker for tumor recurrence. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0945-6317 1432-2307 |
DOI: | 10.1007/s00428-023-03564-z |